MedPath
Found 8 clinical trials|View Analysis
Sort by:

A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3

Phase 1
Recruiting
Conditions
Neoplasm Metastasis
Urinary Bladder Neoplasms
Ureteral Neoplasms
Interventions
Drug: LOXO-435
Drug: Pembrolizumab
First Posted Date
2022-11-14
Last Posted Date
2024-11-18
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
180
Registration Number
NCT05614739
Locations
🇦🇺

Calvary Mater Newcastle, Waratah, New South Wales, Australia

🇫🇷

Gustave Roussy, Villejuif Cedex, France

🇮🇹

UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore, Roma, Italy

and more 54 locations

A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

Phase 1
Active, not recruiting
Conditions
Renal Pelvis Neoplasms
Carcinoma, Transitional Cell
Urinary Bladder Neoplasms
Urologic Neoplasms
Urothelial Cancer
Ureteral Neoplasms
Urethral Neoplasms
Interventions
First Posted Date
2017-09-20
Last Posted Date
2024-12-27
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
348
Registration Number
NCT03288545
Locations
🇺🇸

Piedmont Cancer Institute, Atlanta, Georgia, United States

🇺🇸

Winship Cancer Institute / Emory University School of Medicine, Atlanta, Georgia, United States

🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

and more 103 locations

A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

Phase 2
Completed
Conditions
Urologic Neoplasms
Renal Pelvis Neoplasms
Urinary Bladder Neoplasms
Urothelial Cancer
Urethral Neoplasms
Carcinoma, Transitional Cell
Ureteral Neoplasms
Interventions
Drug: Enfortumab vedotin
First Posted Date
2017-07-17
Last Posted Date
2024-08-27
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
219
Registration Number
NCT03219333
Locations
🇺🇸

Johns Hopkins Medical Center, Baltimore, Maryland, United States

🇺🇸

James Cancer Hospital / Ohio State University, Columbus, Ohio, United States

🇺🇸

University of Pittsburgh Medical Center (UPMC)/Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

and more 78 locations

LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer

Phase 2
Terminated
Conditions
Urethral Neoplasms
Ureteral Neoplasms
Urinary Bladder Neoplasms
Interventions
First Posted Date
2015-11-23
Last Posted Date
2022-11-03
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
8
Registration Number
NCT02612194
Locations
🇺🇸

Levine Cancer Institute, Charlotte, North Carolina, United States

Lymphadenectomy in Urothelial Carcinoma

Not Applicable
Suspended
Conditions
Ureteral Neoplasms
Interventions
Procedure: Nephroureterectomy without lymphadenectomy
Procedure: Lymphadenectomy in conjugation with nephroureterectomy
First Posted Date
2015-11-18
Last Posted Date
2024-01-30
Lead Sponsor
Zealand University Hospital
Target Recruit Count
366
Registration Number
NCT02607709
Locations
🇩🇰

Roskilde Hospital, Roskilde, Denmark

Irreversible Electroporation(IRE) For Unresectable Renal Pelvic and Ureteral Neoplasms

Not Applicable
Completed
Conditions
Renal Pelvic and Ureteral Neoplasms
Interventions
Procedure: rreversible electroporation (IRE)
Device: NanoKnife
First Posted Date
2015-04-30
Last Posted Date
2021-09-05
Lead Sponsor
Fuda Cancer Hospital, Guangzhou
Target Recruit Count
30
Registration Number
NCT02430779
Locations
🇨🇳

Biological treatment center in Fuda cancer hospital, Guangzhou, Guangdong, China

TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma

Phase 2
Completed
Conditions
Urothelial Carcinoma
Ureteral Neoplasms
Ureter Cancer
Neoplasm, Ureteral
Cancer of the Ureter
Interventions
Drug: TRC105
First Posted Date
2011-04-04
Last Posted Date
2017-01-13
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
13
Registration Number
NCT01328574
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium

Phase 2
Completed
Conditions
Bladder Neoplasms
Ureteral Neoplasms
Urethral Neoplasms
Carcinoma, Transitional Cell
First Posted Date
2004-02-16
Last Posted Date
2009-06-04
Lead Sponsor
Achieve Life Sciences
Target Recruit Count
44
Registration Number
NCT00077688
Locations
🇺🇸

Cleveland Clinic Foundation, Cleveland, Ohio, United States

🇺🇸

University of Maryland Medical Center/Greenbaum Cancer Center, Baltimore, Maryland, United States

🇺🇸

University of Washington/Seattle Cancer Care Alliance, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath